228 related articles for article (PubMed ID: 32880368)
1. Repurposing of KLF5 activates a cell cycle signature during the progression from a precursor state to oesophageal adenocarcinoma.
Rogerson C; Ogden S; Britton E; ; Ang Y; Sharrocks AD
Elife; 2020 Sep; 9():. PubMed ID: 32880368
[TBL] [Abstract][Full Text] [Related]
2. The characterization of an intestine-like genomic signature maintained during Barrett's-associated adenocarcinogenesis reveals an NR5A2-mediated promotion of cancer cell survival.
Duggan SP; Behan FM; Kirca M; Zaheer A; McGarrigle SA; Reynolds JV; Vaz GM; Senge MO; Kelleher D
Sci Rep; 2016 Sep; 6():32638. PubMed ID: 27586588
[TBL] [Abstract][Full Text] [Related]
3. MIC-1/GDF15 in Barrett's oesophagus and oesophageal adenocarcinoma.
Fisher OM; Levert-Mignon AJ; Lord SJ; Lee-Ng KK; Botelho NK; Falkenback D; Thomas ML; Bobryshev YV; Whiteman DC; Brown DA; Breit SN; Lord RV
Br J Cancer; 2015 Apr; 112(8):1384-91. PubMed ID: 25867265
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis.
Gharahkhani P; Fitzgerald RC; Vaughan TL; Palles C; Gockel I; Tomlinson I; Buas MF; May A; Gerges C; Anders M; Becker J; Kreuser N; Noder T; Venerito M; Veits L; Schmidt T; Manner H; Schmidt C; Hess T; Böhmer AC; Izbicki JR; Hölscher AH; Lang H; Lorenz D; Schumacher B; Hackelsberger A; Mayershofer R; Pech O; Vashist Y; Ott K; Vieth M; Weismüller J; Nöthen MM; ; ; ; Attwood S; Barr H; Chegwidden L; de Caestecker J; Harrison R; Love SB; MacDonald D; Moayyedi P; Prenen H; Watson RGP; Iyer PG; Anderson LA; Bernstein L; Chow WH; Hardie LJ; Lagergren J; Liu G; Risch HA; Wu AH; Ye W; Bird NC; Shaheen NJ; Gammon MD; Corley DA; Caldas C; Moebus S; Knapp M; Peters WHM; Neuhaus H; Rösch T; Ell C; MacGregor S; Pharoah P; Whiteman DC; Jankowski J; Schumacher J
Lancet Oncol; 2016 Oct; 17(10):1363-1373. PubMed ID: 27527254
[TBL] [Abstract][Full Text] [Related]
5. Impact of surveillance for Barrett's oesophagus on tumour stage and survival of patients with neoplastic progression.
Kastelein F; van Olphen SH; Steyerberg EW; Spaander MC; Bruno MJ;
Gut; 2016 Apr; 65(4):548-54. PubMed ID: 25903690
[TBL] [Abstract][Full Text] [Related]
6. Demographic and phenotypic features of 70 families segregating Barrett's oesophagus and oesophageal adenocarcinoma.
Drovdlic CM; Goddard KA; Chak A; Brock W; Chessler L; King JF; Richter J; Falk GW; Johnston DK; Fisher JL; Grady WM; Lemeshow S; Eng C
J Med Genet; 2003 Sep; 40(9):651-6. PubMed ID: 12960209
[TBL] [Abstract][Full Text] [Related]
7. eRNA profiling uncovers the enhancer landscape of oesophageal adenocarcinoma and reveals new deregulated pathways.
Ahmed I; Yang SH; Ogden S; Zhang W; Li Y; ; Sharrocks AD
Elife; 2023 Feb; 12():. PubMed ID: 36803948
[TBL] [Abstract][Full Text] [Related]
8. Dietary inflammatory index and risk of reflux oesophagitis, Barrett's oesophagus and oesophageal adenocarcinoma: a population-based case-control study.
Shivappa N; Hebert JR; Anderson LA; Shrubsole MJ; Murray LJ; Getty LB; Coleman HG
Br J Nutr; 2017 May; 117(9):1323-1331. PubMed ID: 28571591
[TBL] [Abstract][Full Text] [Related]
9. Expression of neuroepithelial transforming gene 1 is enhanced in oesophageal cancer and mediates an invasive tumour cell phenotype.
Lahiff C; Cotter E; Casey R; Doran P; Pidgeon G; Reynolds J; Macmathuna P; Murray D
J Exp Clin Cancer Res; 2013 Aug; 32(1):55. PubMed ID: 23945136
[TBL] [Abstract][Full Text] [Related]
10. Review article: a conceptual approach to understanding the molecular mechanisms of cancer development in Barrett's oesophagus.
Souza RF; Morales CP; Spechler SJ
Aliment Pharmacol Ther; 2001 Aug; 15(8):1087-100. PubMed ID: 11472311
[TBL] [Abstract][Full Text] [Related]
11. Aneuploidy in targeted endoscopic biopsies outperforms other tissue biomarkers in the prediction of histologic progression of Barrett's oesophagus: A multi-centre prospective cohort study.
Hadjinicolaou AV; van Munster SN; Achilleos A; Santiago Garcia J; Killcoyne S; Ragunath K; Bergman JJGHM; Fitzgerald RC; di Pietro M
EBioMedicine; 2020 Jun; 56():102765. PubMed ID: 32460165
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic biomarkers in progression from non-dysplastic Barrett's oesophagus to oesophageal adenocarcinoma: a systematic review protocol.
Nieto T; Tomlinson CL; Dretzke J; Bayliss S; Dilworth M; Beggs AD; Tucker O
BMJ Open; 2016 Dec; 6(12):e013361. PubMed ID: 27927666
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms in Genes of Relevance for Oestrogen and Oxytocin Pathways and Risk of Barrett's Oesophagus and Oesophageal Adenocarcinoma: A Pooled Analysis from the BEACON Consortium.
Lagergren K; Ek WE; Levine D; Chow WH; Bernstein L; Casson AG; Risch HA; Shaheen NJ; Bird NC; Reid BJ; Corley DA; Hardie LJ; Wu AH; Fitzgerald RC; Pharoah P; Caldas C; Romero Y; Vaughan TL; MacGregor S; Whiteman D; Westberg L; Nyren O; Lagergren J
PLoS One; 2015; 10(9):e0138738. PubMed ID: 26406593
[TBL] [Abstract][Full Text] [Related]
14. A Transcriptional Regulatory Loop of Master Regulator Transcription Factors, PPARG, and Fatty Acid Synthesis Promotes Esophageal Adenocarcinoma.
Ma S; Zhou B; Yang Q; Pan Y; Yang W; Freedland SJ; Ding LW; Freeman MR; Breunig JJ; Bhowmick NA; Pan J; Koeffler HP; Lin DC
Cancer Res; 2021 Mar; 81(5):1216-1229. PubMed ID: 33402390
[TBL] [Abstract][Full Text] [Related]
15. Functional single-nucleotide polymorphism of epidermal growth factor is associated with the development of Barrett's esophagus and esophageal adenocarcinoma.
Menke V; Pot RG; Moons LM; van Zoest KP; Hansen B; van Dekken H; Siersema PD; Kusters JG; Kuipers EJ
J Hum Genet; 2012 Jan; 57(1):26-32. PubMed ID: 22129558
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of Hsp27 in normal oesophagus, Barrett's metaplasia and oesophageal adenocarcinomas.
Soldes OS; Kuick RD; Thompson IA; Hughes SJ; Orringer MB; Iannettoni MD; Hanash SM; Beer DG
Br J Cancer; 1999 Feb; 79(3-4):595-603. PubMed ID: 10027336
[TBL] [Abstract][Full Text] [Related]
17. Evolution and progression of Barrett's oesophagus to oesophageal cancer.
Killcoyne S; Fitzgerald RC
Nat Rev Cancer; 2021 Nov; 21(11):731-741. PubMed ID: 34545238
[TBL] [Abstract][Full Text] [Related]
18. Toenail trace element status and risk of Barrett's oesophagus and oesophageal adenocarcinoma: results from the FINBAR study.
O'Rorke MA; Cantwell MM; Abnet CC; Brockman AJ; Murray LJ;
Int J Cancer; 2012 Oct; 131(8):1882-91. PubMed ID: 22262413
[TBL] [Abstract][Full Text] [Related]
19. Telomerase, hTERT and splice variants in Barrett's oesophagus and oesophageal adenocarcinoma.
Barclay JY; Morris A; Nwokolo CU
Eur J Gastroenterol Hepatol; 2005 Feb; 17(2):221-7. PubMed ID: 15674101
[TBL] [Abstract][Full Text] [Related]
20. Surveillance in patients with long-segment Barrett's oesophagus: a cost-effectiveness analysis.
Kastelein F; van Olphen S; Steyerberg EW; Sikkema M; Spaander MC; Looman CW; Kuipers EJ; Siersema PD; Bruno MJ; de Bekker-Grob EW;
Gut; 2015 Jun; 64(6):864-71. PubMed ID: 25037191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
